RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/29392887http://www.w3.org/2000/01/rdf-schema#comment"Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan-Meier analyses revealed that ARID1A down-regulation was related to a poorer response to paclitaxel-based chemotherapy in patients with TNBCs as measured by the recurrence-free survival probability. The pharmaceutical inhibition with p38MAPK-specific inhibitor SCIO-469 revealed that p38MAPK-related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel-based chemotherapy."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.org/dc/terms/identifier"doi:10.1111/jcmm.13551"xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Kuo C.J."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Lin H.Y."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Lin Y.F."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Tseng I.J."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Chiu H.W."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/author"Chiu I.J."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/date"2018"xsd:gYear
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/name"J Cell Mol Med"xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/pages"2458-2468"xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/title"High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy."xsd:string
http://purl.uniprot.org/citations/29392887http://purl.uniprot.org/core/volume"22"xsd:string
http://purl.uniprot.org/citations/29392887http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/29392887
http://purl.uniprot.org/citations/29392887http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/29392887
http://purl.uniprot.org/uniprot/#_A0A510GDE6-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/#_B4E0K5-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/#_B5TY33-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/#_Q15454-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/#_L7RSM2-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/#_Q16539-mappedCitation-29392887http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/A0A510GDE6http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/L7RSM2http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/29392887
http://purl.uniprot.org/uniprot/Q16539http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/29392887